HRP20160654T1 - 1-(3,3-DIMETILBUTIL)-3-(2-FLUOR-4-METIL-5-(7-METIL-2-(METILAMINO)PIRIDO[2,3-d]PIRIMIDIN-6-IL)FENIL)UREA KAO INHIBITOR Raf KINAZE U LIJEČENJU RAKA - Google Patents
1-(3,3-DIMETILBUTIL)-3-(2-FLUOR-4-METIL-5-(7-METIL-2-(METILAMINO)PIRIDO[2,3-d]PIRIMIDIN-6-IL)FENIL)UREA KAO INHIBITOR Raf KINAZE U LIJEČENJU RAKA Download PDFInfo
- Publication number
- HRP20160654T1 HRP20160654T1 HRP20160654TT HRP20160654T HRP20160654T1 HR P20160654 T1 HRP20160654 T1 HR P20160654T1 HR P20160654T T HRP20160654T T HR P20160654TT HR P20160654 T HRP20160654 T HR P20160654T HR P20160654 T1 HRP20160654 T1 HR P20160654T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- compound
- cancer
- salt
- pyrido
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 5
- 201000011510 cancer Diseases 0.000 title claims 5
- HHCBMISMPSAZBF-UHFFFAOYSA-N LY3009120 Chemical compound CC1=NC2=NC(NC)=NC=C2C=C1C1=CC(NC(=O)NCCC(C)(C)C)=C(F)C=C1C HHCBMISMPSAZBF-UHFFFAOYSA-N 0.000 title claims 3
- 229940123690 Raf kinase inhibitor Drugs 0.000 title 1
- 102000051624 phosphatidylethanolamine binding protein Human genes 0.000 title 1
- 108700021017 phosphatidylethanolamine binding protein Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 229920003083 Kollidon® VA64 Polymers 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 229940117958 vinyl acetate Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Claims (12)
1. Spoj, naznačen time što je 1-(3,3-dimetilbutil)-3-(2-fluor-4-metil-5-(7-metil-2-(metilamino)pirido[2,3-d]pirimidin-6-il)fenil)urea, ili njezina farmaceutski prihvatljiva sol.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 1-(3,3-dimetilbutil)-3-(2-fluor-4-metil-5-(7-metil-2-(metilamino)pirido[2,3-d]pirimidin-6-il)fenil)urea.
3. Spoj u skladu s patentnim zahtjevom 2, koji je 1-(3,3-dimetilbutil)-3-(2-fluor-4-metil-5-(7-metil-2-(metilamino)pirido[2,3-d]pirimidin-6-il)fenil)urea u kristalnom obliku, naznačenom time što ima uzorak difrakcije rendgenskih zraka na prahu s karakterističnim signalima, u 2θ ± 0,2, koji se nalaze na 16,0 i jednom ili više od 6,9, 7,0, 18,2, te 23,2.
4. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu farmaceutski prihvatljivu sol, uz farmaceutski prihvatljivu podlogu.
5. Farmaceutski pripravak, naznačen time što sadrži spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1-3, kao i farmaceutski prihvatljivu podlogu, razrjeđivač ili pomoćnu tvar.
6. Farmaceutski pripravak, naznačen time što sadrži spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1-3, kao i polivinilpirolidon–vinil-acetat (PVP-VA).
7. Farmaceutski pripravak u skladu s patentnim zahtjevom 6, naznačen time što je PVP-VA Kollidon® VA 64.
8. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačeni time što su namijenjeni upotrebi u terapiji.
9. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačeni time što su namijenjeni upotrebi u liječenju raka.
10. Spoj ili sol namijenjeni upotrebi u skladu s patentnim zahtjevom 9, naznačeni time što se rak bira iz skupine koju čine rak štitnjače, rak jajnika, melanom, akuta mijelogena leukemija (AML) i kolorektalni rak.
11. Spoj ili sol namijenjeni upotrebi u skladu s patentnim zahtjevom 10, naznačeni time što je rak melanom.
12. Spoj ili sol namijenjeni upotrebi u skladu s patentnim zahtjevom 10, naznačeni time što je rak kolorektalni rak.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607702P | 2012-03-07 | 2012-03-07 | |
| EP13712005.1A EP2850082B1 (en) | 2012-03-07 | 2013-03-05 | 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido(2,3-d)pyrimidin-6-yl)phenyl)urea as Raf kinase inhibitor for the treatment of cancer |
| PCT/US2013/029084 WO2013134243A1 (en) | 2012-03-07 | 2013-03-05 | 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160654T1 true HRP20160654T1 (hr) | 2016-07-01 |
Family
ID=47884613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160654TT HRP20160654T1 (hr) | 2012-03-07 | 2016-06-10 | 1-(3,3-DIMETILBUTIL)-3-(2-FLUOR-4-METIL-5-(7-METIL-2-(METILAMINO)PIRIDO[2,3-d]PIRIMIDIN-6-IL)FENIL)UREA KAO INHIBITOR Raf KINAZE U LIJEČENJU RAKA |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US8741911B2 (hr) |
| EP (1) | EP2850082B1 (hr) |
| JP (1) | JP2015509536A (hr) |
| KR (1) | KR20140129087A (hr) |
| CN (1) | CN104302646B (hr) |
| AP (1) | AP2014007899A0 (hr) |
| AR (1) | AR090151A1 (hr) |
| AU (1) | AU2013230146B2 (hr) |
| BR (1) | BR112014018528A8 (hr) |
| CA (1) | CA2863673A1 (hr) |
| CL (1) | CL2014002220A1 (hr) |
| CO (1) | CO7010837A2 (hr) |
| CR (1) | CR20140378A (hr) |
| CY (1) | CY1117846T1 (hr) |
| DK (1) | DK2850082T3 (hr) |
| DO (1) | DOP2014000200A (hr) |
| EA (1) | EA024824B1 (hr) |
| EC (1) | ECSP14017584A (hr) |
| ES (1) | ES2584387T3 (hr) |
| HK (1) | HK1202541A1 (hr) |
| HR (1) | HRP20160654T1 (hr) |
| HU (1) | HUE028095T2 (hr) |
| IL (1) | IL234052A (hr) |
| IN (1) | IN2014MN01575A (hr) |
| LT (1) | LT2850082T (hr) |
| MA (1) | MA37316B1 (hr) |
| ME (1) | ME02423B (hr) |
| MX (1) | MX2014010701A (hr) |
| NZ (1) | NZ627454A (hr) |
| PE (1) | PE20142338A1 (hr) |
| PH (1) | PH12014501986A1 (hr) |
| PT (1) | PT2850082T (hr) |
| RS (1) | RS54840B1 (hr) |
| SG (1) | SG11201404969YA (hr) |
| SI (1) | SI2850082T1 (hr) |
| TN (1) | TN2014000375A1 (hr) |
| TW (1) | TW201348233A (hr) |
| UA (1) | UA112340C2 (hr) |
| WO (2) | WO2013134243A1 (hr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR090151A1 (es) * | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| RU2018146886A (ru) * | 2016-06-10 | 2020-07-10 | Новартис Аг | Пути терапевтического применения ингибитора c-raf |
| US10898487B2 (en) | 2016-12-22 | 2021-01-26 | Boehringer Ingelheim International Gmbh | Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors |
| EP3615083A4 (en) * | 2017-04-28 | 2021-05-19 | Zamboni Chem Solutions Inc. | RAF DEGRADATION CONJUGATES |
| SG11202005881YA (en) | 2017-12-21 | 2020-07-29 | Boehringer Ingelheim Int | Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors |
| JP7161849B2 (ja) * | 2018-01-24 | 2022-10-27 | 株式会社クラレ | 第一級アミンの製造方法 |
| CA3089630A1 (en) | 2018-01-31 | 2019-08-08 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of mastocytosis |
| SG11202007198WA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| EP3902547B1 (en) | 2018-12-28 | 2023-09-20 | Deciphera Pharmaceuticals, LLC | Csf1r inhibitors for use in treating cancer |
| SI3921030T1 (sl) | 2019-02-06 | 2024-03-29 | Eli Lilly And Company | Derivati 1-((2-(2,2,2-trifluoroetoksi)piridin-4-il)metil)sečnine kot ojačevalci kcnq |
| TW202106684A (zh) | 2019-05-03 | 2021-02-16 | 美商奇奈特生物製藥公司 | Raf激酶抑制劑 |
| CN114072397A (zh) | 2019-05-10 | 2022-02-18 | 德西费拉制药有限责任公司 | 杂芳基氨基嘧啶酰胺自噬抑制剂及其使用方法 |
| EP4342469A3 (en) | 2019-05-10 | 2024-06-19 | Deciphera Pharmaceuticals, LLC | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| CN114258318B (zh) | 2019-06-17 | 2024-09-20 | 德西费拉制药有限责任公司 | 氨基嘧啶酰胺自噬抑制剂及其使用方法 |
| TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| MX2022001863A (es) | 2019-08-12 | 2022-05-30 | Deciphera Pharmaceuticals Llc | Metodos para tratar los tumores del estroma gastrointestinal. |
| DK4084778T3 (da) | 2019-12-30 | 2023-12-11 | Deciphera Pharmaceuticals Llc | Amorfe kinaseinhibitorformuleringer og fremgangsmåder til anvendelse deraf |
| KR20220123058A (ko) | 2019-12-30 | 2022-09-05 | 데시페라 파마슈티칼스, 엘엘씨. | 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물 |
| EP4157836A1 (en) | 2020-06-02 | 2023-04-05 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| US11407737B2 (en) | 2020-09-18 | 2022-08-09 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| WO2022081469A1 (en) | 2020-10-12 | 2022-04-21 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| US12064421B2 (en) | 2020-11-02 | 2024-08-20 | Boehringer Ingelheim International Gmbh | Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors |
| KR20230121758A (ko) | 2020-11-18 | 2023-08-21 | 데시페라 파마슈티칼스, 엘엘씨. | Gcn2 및 perk 키나제 억제제 및 그의 사용 방법 |
| TW202241885A (zh) | 2020-12-22 | 2022-11-01 | 大陸商上海齊魯銳格醫藥研發有限公司 | Ｓｏｓ１抑制劑及其用途 |
| IL307908A (en) | 2021-04-23 | 2023-12-01 | Kinnate Biopharma Inc | Cancer treatment with a RAF inhibitor |
| US12065427B2 (en) | 2021-04-29 | 2024-08-20 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating STING |
| CN118574835A (zh) | 2021-12-01 | 2024-08-30 | 勃林格殷格翰国际有限公司 | 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物 |
| CN118591540A (zh) | 2021-12-01 | 2024-09-03 | 勃林格殷格翰国际有限公司 | 包含环状2-氨基-3-氰基噻吩的kras降解化合物 |
| TW202337432A (zh) | 2021-12-01 | 2023-10-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
| EP4441050A1 (en) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| EP4441054A1 (en) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| CA3240980A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2023108103A1 (en) | 2021-12-09 | 2023-06-15 | Deciphera Pharmaceuticals, Llc | Raf kinase inhibitors and methods of use thereof |
| CN118434735A (zh) | 2021-12-23 | 2024-08-02 | 勃林格殷格翰国际有限公司 | 8-氮杂喹唑啉作为脑渗透sos1抑制剂 |
| WO2023173017A1 (en) * | 2022-03-09 | 2023-09-14 | Blossomhill Therapeutics, Inc. | Kras inhibitors for treating disease |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| WO2024088991A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
| US20240174641A1 (en) | 2022-10-26 | 2024-05-30 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
| US20240174642A1 (en) | 2022-10-26 | 2024-05-30 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1447405A4 (en) * | 2001-10-17 | 2005-01-12 | Kirin Brewery | QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS |
| US20080207617A1 (en) * | 2002-10-29 | 2008-08-28 | Kirin Beer Kabushiki Kaisha | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| US8901137B2 (en) | 2010-02-09 | 2014-12-02 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors |
| AR090151A1 (es) * | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
-
2013
- 2013-02-26 AR ARP130100576A patent/AR090151A1/es unknown
- 2013-02-27 TW TW102107122A patent/TW201348233A/zh unknown
- 2013-03-05 LT LTEP13712005.1T patent/LT2850082T/lt unknown
- 2013-03-05 IN IN1575MUN2014 patent/IN2014MN01575A/en unknown
- 2013-03-05 CN CN201380012913.9A patent/CN104302646B/zh not_active Expired - Fee Related
- 2013-03-05 SG SG11201404969YA patent/SG11201404969YA/en unknown
- 2013-03-05 JP JP2014561029A patent/JP2015509536A/ja not_active Ceased
- 2013-03-05 PT PT137120051T patent/PT2850082T/pt unknown
- 2013-03-05 DK DK13712005.1T patent/DK2850082T3/en active
- 2013-03-05 RS RS20160416A patent/RS54840B1/sr unknown
- 2013-03-05 US US13/785,575 patent/US8741911B2/en not_active Expired - Fee Related
- 2013-03-05 WO PCT/US2013/029084 patent/WO2013134243A1/en active Application Filing
- 2013-03-05 SI SI201330188A patent/SI2850082T1/sl unknown
- 2013-03-05 US US14/383,799 patent/US9334267B2/en not_active Expired - Fee Related
- 2013-03-05 BR BR112014018528A patent/BR112014018528A8/pt not_active IP Right Cessation
- 2013-03-05 KR KR1020147024732A patent/KR20140129087A/ko active IP Right Grant
- 2013-03-05 EA EA201491456A patent/EA024824B1/ru not_active IP Right Cessation
- 2013-03-05 EP EP13712005.1A patent/EP2850082B1/en active Active
- 2013-03-05 WO PCT/US2013/029098 patent/WO2013134252A1/en active Application Filing
- 2013-03-05 ES ES13712005.1T patent/ES2584387T3/es active Active
- 2013-03-05 HU HUE13712005A patent/HUE028095T2/en unknown
- 2013-03-05 ME MEP-2016-124A patent/ME02423B/me unknown
- 2013-03-05 MX MX2014010701A patent/MX2014010701A/es unknown
- 2013-03-05 AP AP2014007899A patent/AP2014007899A0/xx unknown
- 2013-03-05 CA CA2863673A patent/CA2863673A1/en not_active Abandoned
- 2013-03-05 PE PE2014001381A patent/PE20142338A1/es not_active Application Discontinuation
- 2013-03-05 AU AU2013230146A patent/AU2013230146B2/en not_active Ceased
- 2013-03-05 NZ NZ627454A patent/NZ627454A/en not_active IP Right Cessation
- 2013-03-05 MA MA37316A patent/MA37316B1/fr unknown
- 2013-05-03 UA UAA201409109A patent/UA112340C2/uk unknown
-
2014
- 2014-07-24 CO CO14161404A patent/CO7010837A2/es unknown
- 2014-08-11 IL IL234052A patent/IL234052A/en not_active IP Right Cessation
- 2014-08-12 CR CR20140378A patent/CR20140378A/es unknown
- 2014-08-21 CL CL2014002220A patent/CL2014002220A1/es unknown
- 2014-09-03 TN TNP2014000375A patent/TN2014000375A1/fr unknown
- 2014-09-04 DO DO2014000200A patent/DOP2014000200A/es unknown
- 2014-09-05 EC ECIEPI201417584A patent/ECSP14017584A/es unknown
- 2014-09-05 PH PH12014501986A patent/PH12014501986A1/en unknown
-
2015
- 2015-03-26 HK HK15103082.6A patent/HK1202541A1/xx unknown
-
2016
- 2016-06-10 HR HRP20160654TT patent/HRP20160654T1/hr unknown
- 2016-07-22 CY CY20161100719T patent/CY1117846T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160654T1 (hr) | 1-(3,3-DIMETILBUTIL)-3-(2-FLUOR-4-METIL-5-(7-METIL-2-(METILAMINO)PIRIDO[2,3-d]PIRIMIDIN-6-IL)FENIL)UREA KAO INHIBITOR Raf KINAZE U LIJEČENJU RAKA | |
| JP2015509536A5 (hr) | ||
| IL228968A (en) | Pyrazolo [4,3– d] compounds pyrimidine kinase suppressants, preparations and their uses | |
| HUS2200003I1 (hu) | Pirrolo [2,3-D]pirimidin származékok mint a Janus-kinázok (JAK) inhibitorai | |
| HRP20180746T4 (hr) | Supstituirani spojevi pirazolo[1,5-]pirimidina kao inhibitori trk kinaze | |
| HRP20170162T1 (hr) | HETEROARIL SUPSTITUIRANI PIROLO[2,3-b]PIRIDINI I PIROLO[2,3-b]PIRIMIDINI KAO INHIBITORI JANUS KINAZE | |
| HRP20171151T1 (hr) | Inhibitori cdc7 | |
| AR120339A2 (es) | CRISTALES DE SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA | |
| SI3077397T1 (sl) | 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)pirazolo(1,5-A)pirimidin-3- karboksamidna spojina, koristna kot inhibitor kinaze ATR, njena priprava, različne trdne oblike in njeni radioaktivno označeni derivati | |
| ZA201700035B (en) | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof | |
| HRP20210681T1 (hr) | Kristalne soli (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroizokinolin-2(1h)-il)-2-hidroksipropil)pirimidin-4-karboksamida | |
| HRP20160030T1 (hr) | Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace) | |
| EA201390199A1 (ru) | 2-замещенные-8-алкил-7-оксо-7,8-дигидропиридо[2,3-d]пиримидин-6-карбонитрилы и их применение | |
| PT3345907T (pt) | Compostos de pirazolo[3,4-d]pirimidina ou sais dos mesmos | |
| JP2016523270A5 (hr) | ||
| HRP20201492T1 (hr) | Hidrokloridne soli n-(cijanometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida | |
| HRP20151324T1 (hr) | Soli nilotiniba i njihovi kristalni oblici | |
| EA201290147A1 (ru) | Пирроло[2,3-d]пиримидиновые соединения | |
| CL2012003564A1 (es) | Compuestos derivados de heteroaril limidazolona :composición farmacéutica;uso de los compuestos para la inhibición de jak1,jak2 y jak3; y combinaciones farmacéuticas. | |
| BR112012019511A2 (pt) | compostos de pirrolo [2,3-d] pirimidina como inibidores de jak. | |
| HRP20190814T1 (hr) | 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-on, njegove soli i postupci uporabe | |
| IL185870A (en) | H8-pyrido [3,2 – d] pyramidine-7-ben histones preserved in positions 2, 4, 8 that act as csbp / rk / p38 kinase inhibitors and their pharmaceuticals containing them | |
| HK1215248A1 (zh) | 被取代的吡唑並 嘧啶化合物、其製備及作為σ受體配體的用途 | |
| HK1198441A1 (en) | Pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma ligands [34-d] | |
| PL3008063T3 (pl) | Pochodne 4-amino-6-(2,6-dichlorofenylo)-2-(fenyloamino)pirydo(2,3- d)pirymidyn-7(8h)-onu, ich synteza oraz zastosowania |